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Centro de Patoge´nese Molecular, Faculty of Pharmacy, UniVersity of Lisbon, Lisbon 1600-083, Portugal,
National Institute of Neurological Disorders and Stroke, National Institute of General Medical Sciences,
National Institutes of Health, Bethesda, Maryland 20892, Department of Chemistry, Faculty of Sciences and
Technology, New UniVersity of Lisbon, 2825-114 Monte de Caparica, Portugal, and Departments of Medicine,
and Genetics, Cell Biology, and DeV lopment, UniVersity of Minnesota Medical School,
Minneapolis, Minnesota 55455
ReceiVed October 9, 2002; ReVised Manuscript ReceiVed January 15, 2003
ABSTRACT: Bax is a potent pro-apoptotic member of the Bcl-2 protein family that localizes to the
mitochondrial membrane during apoptosis. Tauroursodeoxycholic acid (TUDCA) modulates the apoptotic
threshold, in part, by preventing Bax translocation both in vitro and in vivo. The mechanisms by which
Bax induces and TUDCA inhibits release of cytochromec are unclear. We show here that recombinant
Bax protein induced cytochromec release in isolated mitochondria without detectable swelling. Co-
incubation with TUDCA prevented efflux of mitochondrial factors and proteolytic processing of caspases
in cytosolic extracts. Spectroscopic analyses of mitochondria exposed to Bax revealed increased polarity
and fluidity of the membrane lipid core as well as altered protein order, indicative of Bax binding, together
with loss of spin-label paramagnetism, characteristic of oxidative damage. TUDCA markedly abrogated
the Bax-induced membrane perturbation. In conclusion, our results indicate that Bax protein directly induces
cytochromec release from mitochondria through a mechanism that does not require the permeability
transition. Rather, it is accompanied by changes in the organization of membrane lipids and proteins.
TUDCA is a potent inhibitor of Bax association with mitochondria. Thus, TUDCA modulates apoptosis
by suppressing mitochondrial membrane perturbation through pathways that are also independent of the
mitochondrial permeability transition.
The Bcl-2 family of proteins plays a key role in regulating
mitochondrial-mediated programmed cell death. The pro-
death members such as Bax regulate the release of apopto-
genic proteins from mitochondria, thus inducing apoptosis,
whereas the anti-death members such as Bcl-2 and Bcl-xL
promote cell survival (1). Pro- and antiapoptotic Bcl-2
proteins can either reside in the cytosol or be associated with
other intracellular sites including the outer mitochondrial
membrane, the nuclear envelope, and the endoplasmic
reticulum. Membrane anchoring is presumably facilitated by
a hydrophobic stretch of amino acids present at the COOH
terminus (2, 3). Certain apoptotic stimuli are transduced to
mitochondria through BH3-only proteins or additional path-
ways. The signals can either be neutralized by antiapoptotic
factors, such as Bcl-2, or further transmitted through Bax
and Bak. These proapoptotic molecules undergo conforma-
tional changes that allow for their translocation from cytosol
to the mitochondrial membrane (4). This results in the
formation of pores and subsequent release of intermembrane
space proteins, and/or destabilization of the mitochondrial
outer membrane (5). In addition to the activation of apoptotic
pathways, the loss of mitochondrial function may itself
induce cell death.
Cytochromec, adenylate kinase, Smac/DIABLO, pro-
caspases, and apoptosis-inducing factor have all been re-
ported to enter the cytosol with disruption of the mitochon-
drial membrane (6-11). Once released, cytochromec binds
to apoptosis-activating factor 1 (Apaf-1)1 and forms a
cytosolic protein complex that also includes dATP and
procaspase-9 (12). This leads to caspase-9 activation, which
in turn activates downstream caspase-mediated events that
ultimately lead to the morphologic changes characteristic of
apoptosis. Alternatively, since cytochromec release can
precede loss of the mitochondrial transmembrane potential
(∆Ψm) (13, 14), it is conceivable that Bax itself creates pores
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in the outer membrane allowing escape of intermembrane
proteins (15-17). Bax was indeed shown to act as a pore-
forming protein (16, 18, 19) that can also affect activity of
the voltage-dependent anion channel (20) and the adenine
nucleotide transporter (21). Further, Bax-induced release of
cytochromec may secondarily result in megapore opening
from either uncoupled oxidative phosphorylation or caspase-
mediated cleavage of mitochondrial proteins (22).
Thus, Bax plays a key role as a central regulator in the
release of mitochondrial intermembrane space proteins.
However, it remains unclear as to how the translocation of
Bax from cytosol to mitochondria mediates the downstream
pathways to apoptosis. It appears that the release of proapo-
ptotic factors can occur through at least two major models
involving Bax interaction with the mitochondrial membrane
(23). While formation of the “Bax channel” allows the release
of cytochromec, opening of the permeability transition pore
results in loss of∆Ψm, swelling of the mitochondrial matrix
and nonselective release of intermembrane space proteins.
However, it has recently been shown that oligomeric Bax
can form rather large pores. This finding challenges the
notion that outer membrane rupture is required to release
apoptotic proteins larger than cytochromec, such as Smac/
DIABLO and the apoptosis inducing factor (24). In addition,
Bax was demonstrated to permeabilize liposomes without
the requirement of the voltage-dependent anion channel and
the adenine nucleotide transporter.
The dihydroxy bile acid ursodeoxycholic acid (UDCA)
has been in widespread clinical use for the past 20 years,
initially for gallstone dissolution and subsequently for the
treatment of chronic cholestatic liver diseases (25). Despite
its clinical efficacy, the precise mechanism(s) by which
UDCA improves liver function is still unclear. In recent
years, however, it has become evident that UDCA is capable
of exerting direct effects at the cellular, subcellular, and
molecular levels through multiple mechanisms including the
stabilization of cell membranes (26). In addition, we have
shown that UDCA and its taurine conjugated derivative,
tauroursodeoxycholic acid (TUDCA), play a unique role in
regulating the apoptotic threshold in both hepatic and
nonhepatic cells (27). Through both direct and indirect
pathways, these bile acids prevent several apoptotic events,
such as permeability transition, translocation of the proapo-
ptotic protein Bax to mitochondria, release of cytochrome
c, activation of cytosolic caspase, and cleavage of the nuclear
enzyme poly(ADP-ribose) polymerase (PARP) (28, 29).
Thus, as general modulators of cell survival, UDCA and
TUDCA are also potential therapeutic agents in the treatment
of nonliver diseases, such as neurodegenerative disorders
associated with increased levels of apoptosis (30, 31).
In the present study, we investigated the effect of TUDCA
on Bax-mediated structural changes in the lipid and protein
environment of the mitochondrial membrane. Using spec-
troscopic analyses of isolated mitochondria exposed to
recombinant Bax, we determined that the proapoptotic
protein modifies the polarity and fluidity of the membrane
lipid core together with altered protein order. These changes
are consistent with loose association of Bax with the outer
membrane resulting in cytochromec release in the absence
of mitochondrial swelling. TUDCA is a potent suppressor
of Bax-induced alterations, in part, by preventing the binding
of Bax protein to mitochondria. The results suggest that
TUDCA can modulate apoptosis by preventing mitochondrial
perturbation through pathways that are also independent of
the mitochondrial permeability transition.
MATERIAL AND METHODS
Expression and Purification of Recombinant Bax.Full-
length recombinant human Bax was expressed by subcloning
the cDNA of human Bax into the Ndel/Sapl site of pTYB1
vector as described (32). The Bax Ptyb construct was
transformed into the BL21DE3 strain ofEscherichia coli.
The expression of the Bax protein was induced with IPTG
at 37 °C. Bax was incubated on the chitin bead affinity
column (New England BioLabs, Inc., Beverly, MA) and
eluted using 30 mM dithiothreitol. The protein was further
purified by ion-exchange chromatography to a single band
on a sodium dodecyl sulfate (SDS)-polyacrylamide silver
stained gel. Bax was then dissolved in 20 mM Tris-HCl, pH
8.0, 2 mM EDTA, and 0.5 mM NaCl for use in all
experiments.
Isolation of Rat LiVer Mitochondria.Low calcium liver
mitochondria were isolated from adult male 200-250 g
Wistar rats as previously described (28, 33, 34). Following
isolation, mitochondria were kept on ice for up to 3 h. Protein
concentrations were determined using the Bio-Rad protein
assay (Bio-Rad Laboratories, Hercules, CA). All animal
procedures were in accordance with theNIH Guide for the
Care and Use of Laboratory Animals, and were approved
by our Institutional Animal Care and Use Committee.
Mitochondrial Membrane Permeability Transition, Cyto-
chrome c Release and Bax Binding. Mitochondrial membrane
permeability was determined using a spectrophotometric
assay measuring high amplitude rapid changes in mitochon-
drial volume as described (35-36) with modifications.
Briefly, mitochondria (0.75-1 mg of protein) were incubated
in 1 mL of Chelex-100-treated respiration buffer containing
10 mM HEPES, 10 mM succinate, 215 mM mannitol, 71
mM sucrose, pH 7.4 at 25°C, and swelling was monitored
at 540 nm in a Beckman DU 64 spectrophotometer. Basal
levels of absorbance were measured for 5 min, and the optical
density was monitored for 1, 5, 20, and 60 min after the
addition of 0.5, 1, or 2µM Bax. In the coincubation studies,
mitochondria were preincubated with either 500µM TUD-
CA, or 5µM cyclosporine A (Sigma Chemical Co., St. Louis,
MO) for 5 min at 25°C prior to adding Bax for another 5
min.
Following the permeability assays, mitochondria were
centrifuged at 12000g for 3 min at 4 °C. Release of
cytochromec, loss of cytochromec oxidase subunit II, and
binding of Bax were determined by Western blot analysis
of both supernatant and mitochondrial pellets. In brief,
proteins were separated on a 15% SDS-polyacrylamide gel.
Following electrophoretic transfer onto nitrocellulose mem-
branes, the immunoblots were incubated with 15% H2O2 for
15 min at room temperature. Blots were sequentially
incubated with 5% milk blocking solution, primary mono-
clonal antibody to cytochromec (PharMingen, San Diego,
CA) at a dilution of 1:5000 overnight at 4°C, and finally
with secondary goat anti-mouse IgG antibody conjugated
with horseradish peroxidase for 2 h atroom temperature. In
addition, blots were probed with primary polyclonal antibody
to Bax (Santa Cruz Biotechnology, Santa Cruz, CA) at a
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dilution of 1:500, and then with secondary anti-rabbit
antibody conjugated with horseradish peroxidase. Finally,
the isolated mitochondria were incubated with primary
monoclonal antibody to cytochromec oxidase subunit II
(Molecular Probes, Eugene, OR). They were then processed
for detection of cytochromec, Bax, and cytochromec
oxidase using the enhanced chemiluminescence light (ECL)
system from Amersham Life Science, Inc. (Arlington
Heights, IL).
Carbonate Extraction of Bax from Mitochondria.To
distinguish between Bax binding and insertion into the
mitochondrial membrane, we performed carbonate extraction
of Bax in the presence and absence of either TUDCA or
cyclosporine A. In brief, after the incubation assays, mito-
chondria were pelleted at 12000g for 3 min at 4°C and then
resuspended in 10 mM HEPES, pH 7.6. Following addition
of 1 mM phenylmethylsulfonyl fluoride and freshly made
0.2 M sodium carbonate, samples were kept on ice for 30
min and then centrifuged at 225000g for 30 min at 4°C.
The supernatant was removed and precipitated using trichlo-
roacetic acid. Only loosely associated Bax was extracted with
carbonate and identified by Western blot analysis.
Glutamate Dehydrogenase and Citrate Synthase Release.
Following incubation with Bax, mitochondria were pelleted
at 12000g for 3 min at 4°C. Glutamate dehydrogenase and
citrate synthase activities were determined by NADH
production in supernatant by spectrophotometric analysis at
340 nm and 25°C, according to the manufacturer’s recom-
mendation. Total enzyme activity in mitochondria was
determined by disruption of the mitochondria with 0.5%
Triton X-100 (Roche Applied Science, Mannheim, Ger-
many).
Mitochondria-Dependent Caspase ActiVation. Cytosolic
protein extracts were prepared from primary rat hepatocytes.
Cells were isolated from male Sprague-Dawley rats (200-
250 g) by collagenase perfusion as described previously (37).
Briefly, rats were anesthesized with phenobarbitol and their
livers were perfused with 0.05% collagenase. Hepatocyte
suspensions were obtained by passing digested livers through
125 µm gauze and washing the cells in modified Eagle’s
medium (MEM; Atlanta Biologicals, Inc., Norcross, GA).
Cell viability was determined by trypan blue exclusion and
was typically 85-90%. After isolation, hepatocytes were
resuspended in William’s E medium supplemented with 26
mM sodium bicarbonate, 23 mM HEPES, 0.01 U/mL insulin,
2 mM L-glutamine, 10 nM dexamethasone, 5.5 mM glucose,
and then plated on Primaria tissue culture dishes (Becton
Dickinson Labware, Lincoln Park, NJ) at 1.0× 106 cells/
mL. Cells were maintained at 37°C in a humidified
atmosphere of 5% CO2 for 3 h. Plates were then washed
with medium to remove dead cells, and then incubated in
William’s E medium containing 10% heat-inactivated FBS
for 24 h. Hepatocytes were harvested by centrifugation at
600g for 5 min at 4°C. The cell pellet was washed once in
ice-cold PBS and resuspended with extraction buffer con-
taining 10 mM Tris-HCl, pH 7.6, 5 mM MgCl2, 1.5 mM
KAc, 2 mM dithiothreitol, supplemented with the Complete
protease inhibitor cocktail (Roche Applied Science). After
disruption by 20 strokes of a glass homogenizer, the
homogenates were centrifuged twice at 600g for 10 min at
4 °C to remove unbroken cells and nuclei. The supernatant
was removed and centrifuged at 3000g for 10 min at 4°C.
The resulting cytosolic fraction was used for assaying
mitochondria-dependent caspase activation.
Supernatants (10µL) were recovered from mitochondria
treated with either Bax, TUDCA, Bax+ TUDCA or no
addition (control) and incubated with cytosolic protein extract
(10 µL) at 30 °C for 1 h. Aliquots were used for caspase-
3-like activity and for Western blot analysis of caspase-3
processing. Caspase processing and activation was initiated
by addition of 1 mM dATP (38).
Caspase ActiVity and Proteolytic Processing.Caspase
activity was determined by the ability of the enzyme to cleave
the chromophorep-nitroanilide (pNA) from the enzyme
substrateN-acetyl-Asp-Glu-Val-Asp-pNA (DEVD-pNA;
Sigma Chemical Co.). The proteolytic reaction was carried
out in isolation buffer, containing 10 mM Tris-HCl, pH 7.6,
5 mM MgCl2, 1.5 mM KAc, 2 mM dithiothreitol, supple-
mented with the Complete protease inhibitor cocktail, after
adding 20µg of cytosolic protein and 50µM DEVD-pNA.
The reaction mixtures were incubated at 37°C for 2 h, and
the formation of pNA was measured at 405 nm using a 96-
well plate reader. Caspase-3 processing was determined from
cytosolic proteins separated by 15% SDS-polyacrylamide
gel electrophoresis. After membrane transfer, the blots were
probed with primary rabbit polyclonal antibody to caspase-3
(Santa Cruz Biotechnology) at a dilution of 1:1000, and
subsequently incubated with secondary anti-rabbit antibody
conjugated with horseradish peroxidase. Finally, membranes
were processed for active caspase-3 detection using the ECL
system (Amersham Life Science, Inc.).
RNA Isolation and RT-PCR.TUDCA-induced changes in
Bax expression from isolated hepatocytes were determined
by RT-PCR. Total RNA was extracted from rat primary
hepatocytes exposed to 50µM TUDCA for 36 h using the
TRIZOL reagent from Invitrogen (Grand Island, NY). For
RT-PCR, 5µg of total RNA was reverse-transcribed using
oligo(dT) (IDT, Inc., Coralville, IA) and SuperScript II
reverse transcriptase (Invitrogen). Specific oligonucleotide
primer pairs were incubated with cDNA template for PCR
amplification using the Expand High Fidelity PCR system
from Roche Applied Science. The following sequences were
used as primers: Bax sense primer, 5’-TGGTTGCCCTTTTC-
TACTTTG-3’, and Bax antisense primer, 5’-GAAGTAG-
GAAAGGAGGCCATC-3’; â-actin sense primer, 5’-TGC-
CCATCTATGAGGGTTACG-3’, and â-actin antisense
primer, 5’-TAGAAGCATTTGCGGTGCACG-3’. The prod-
uct of constitutively expressedâ-actin mRNA served as
control.
Electron Paramagnetic Resonance(EPR) Spectroscopy
and Spin-Labeling.Changes in membrane structure were
measured by EPR spectroscopy using paramagnetic reporter
groups incorporated into membranes. The polarity of mito-
chondrial membrane lipids was examined at varying depths
with 5- and 16-doxyl stearic acid (5-DSA and 16-DSA) spin
labels (Sigma Chemical Co.), containing a nitroxide group
at different positions along the hydrocarbon chain of the
stearic acid molecule (39-41). The 5-DSA probe resides near
the lipid-water interface, while the 16-DSA localizes deeper
in the lipid bilayer. The isotropic splitting factora0 is a
reliable parameter of the environment of these probes, and
calculated from direct measurements of the parallel and
perpendicular components of the hyperfine tensor of the spin
label. A higha0 reflects increased polarity of the membrane.
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In addition, alterations in membrane dynamic properties of
the 5-DSA probe, showing restricted motion in the mem-
brane, were evaluated by measuring the outer half-width at
half-height of the low-field extremum (∆l). The larger the
∆l, the more motion and less order in the local microenvi-
ronment reported by the nitroxide group. For the 16-DSA
spin label, showing a higher degree of motional freedom,
the ratio of the height of the low-field and the center-field
line (h+1/h0) was used as an empirical measurement of
membrane lipid organization (42, 43). Finally, we also tested
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl (4-maleimido-
TEMPO) label (Sigma Chemical Co.), which binds to the
sulfhydryl groups of proteins. It provides information on the
mobility of protein reactive groups by measuring changes
in structure of protein-rich membranes at the surface level
(41, 44, 45). The ratio of the height of the midline to the
height of the high-field line of the spectrum (h0/h-1) reflects
the freedom of motion of this probe at its binding site. A
high ratio indicates a low freedom of motion.
All spin labels were dissolved in chloroform, separated
into 1 µg aliquots, evaporated under nitrogen, and left under
vacuum for 2 h. Freshly isolated intact mitochondria (10-
50 µg of protein) were incubated in spin label-coated tubes
with gentle shaking for 90 min at 37°C (5- and 16-DSA) or
for 1 min at 22°C (4-maleimido-TEMPO).
Mitochondrial membrane lipid peroxidation was also
assessed using EPR as described previously (46). In brief,
freshly isolated mitochondria (5-10 µg of protein) were
incubated with a membrane-associated, oxidation-sensitive,
paramagnetic probe 5-DSA (1µg aliquots), with gentle
agitation for 20 min at 22°C. Increased production of
reactive oxygen species results in loss of paramagnetism of
the probe, and hence loss of signal amplitude, measured as
the height of the center field-line of the spectrum.
Labeled mitochondrial membranes were then exposed to
Bax (0.5µM) in Chelex-100-treated respiration buffer for 5
min at 22°C. In co-incubation studies, labeled mitochondria
were pretreated with either TUDCA (500µM) or cyclospo-
rine A (5 µM) for 5 min, which remained in the incubation
medium after adding Bax. However, in washout experiments,
TUDCA was removed from the media by centrifugation of
the mitochondrial suspension and only then Bax was added
to the pellet for an additional 5 min. After incubations, the
mitochondrial suspension was spun at 12000g for 3 min, and
the pellet resuspended in respiration buffer (60µL). Samples
were then aspirated into glass capillaries, sealed at both ends,
and introduced in standard 4-mm quartz tubes containing
silicone oil for thermal stability. All spectra were acquired
at 9.8 GHz (X-band) on a Bruker EMX EPR spectrometer
(Bruker, Karlsruhe, Germany) using a rectangular cavity
(model ER 4102ST) and 100 kHz field modulation fre-
quency, 1.05 G modulation amplitude, and 20 mW micro-
wave power, at 22°C.
RESULTS
Bax Directly Induces Cytochrome c Release from Isolated
Mitochondria without Mitochondrial Swelling. We examined
the effect of Bax on cytochromec release by adding full-
length recombinant Bax to mitochondria isolated from rat
liver and energized through complex II with succinate.
Cytochromec release was then determined by Western blot
analysis of both mitochondrial pellets and supernatants. Bax
protein alone was sufficient to trigger a marked efflux of
cytochromec, since supernatants from Bax-treated mito-
chondria contained greater amounts of cytochromec com-
pared to untreated controls (Figure 1A). The release of
cytochromec was dependent on the concentrations of Bax
protein. In fact, mitochondria exposed to 2µM Bax released
approximately 90% of their total cytochromec after 5-min
incubation. Moreover, kinetic experiments performed with
the lowest concentration of Bax showed that cytochromec
release was already detectable after 1 min incubation and
continued to increase thereafter. Interestingly, the concentra-
tion of 0.5µM Bax used for most of the studies was within
a physiological range. Similar and even greater levels of
endogenous Bax have been detected in human tumor cells
(15, 16) and in cells following exposure to DNA-damaging
agents (47).
Mitochondrial swelling, a colloidosmotic process that is
observed during permeability transition induction (48, 49)
was undetectable after 5 min exposure to Bax protein and
remained insignificant to at least 60 min of incubation (Figure
1B). In contrast, the addition of Ca2+ or deoxycholic acid to
isolated mitochondria induced a rapid, cyclosporine A-
sensitive swelling under otherwise identical conditions (data
not shown). Thus, the release of cytochromec induced by
Bax occurs through a mechanism different from that of Ca2+
and deoxycholic acid-induced toxicity. In the isolated mi-
tochondria, Bax did not trigger opening of the mitochondrial
megapore leading to permeability transition and the charac-
teristic swelling.
TUDCA PreVents Bax-induced Release of Pro-apoptotic
Factors that Trigger ActiVation and Processing of Cytosolic
Caspases.We have shown that TUDCA can abrogate the
FIGURE 1: Purified recombinant Bax directly induces cytochrome
c release from isolated mitochondria in the absence of mitochondrial
swelling. (A) Mitochondria were isolated from rat liver and
incubated with no addition (control), 0.5, 1, or 2µM Bax for 5
min (left). In addition, mitochondria were incubated with 0.5µM
Bax for 0 (control), 1, 5, 20, or 60 min (right). Cytochromec release
was assayed in supernatants by Western blot analysis. Following
SDS-polyacrylamide gel electrophoresis and transfer, the nitrocel-
lulose membranes were incubated with a monoclonal antibody to
cytochromec, and the 15-kDa protein was detected using ECL
chemiluminescence. (B) Basal levels of absorbance of mitochondrial
suspensions were measured at 540 nm for 5 min. After the addition
of 0.5 µM Bax (arrow), the optical density was monitored for an
additional 5 min.
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effect of several activators of the permeability transition in
isolated mitochondria (28, 29). Although Bax did not affect
mitochondrial swelling, we examined whether TUDCA
influenced Bax-induced cytochromec release. Cytochrome
c protein levels were determined by Western blot analysis
in mitochondrial pellets and supernatants following incuba-
tion with Bax, in the presence or absence of TUDCA. Very
low levels of cytochromec were detected in mitochondria
after incubation with Bax alone, while supernatant levels
were markedly increased (Figure 2). Moreover, cytochrome
c oxidase was not significantly changed in the mitochondrial
pellet and, therefore, remained undetectable in supernatants,
consistent with the absence of mitochondrial disruption (data
not shown). Similarly, less than 2% of the matrix proteins
glutamate dehydrogenase and citrate synthase were released
after 5-min exposure to Bax. Together, these results suggest
that cytochromec release occurs because of perturbation of
the outer mitochondrial membrane and not simply organelle
bursting. Addition of TUDCA to the incubation media
significantly reduced Bax-associated release of cytochrome
c (p < 0.01). In fact, after 1, 5, 20, and 60 min of incubation
with Bax plus TUDCA, cytochromec release was reduced
by >50% at 1 min to almost 75% at 60 min, compared with
Bax alone (Table 1). Thus, in less than 1 min TUDCA was
able to reduce the efflux of cytochromec to half the
maximum amount released by Bax alone. In contrast,
cyclosporine A did not protect against Bax-induced cyto-
chrome c efflux, again suggesting that the effect was
independent of the permeability transition. In addition,
hydrophobic deoxycholic acid aggravated and hydrophilic
taurocholic acid did not alter Bax-induced changes in
supernatant cytochromec levels (data not shown).
Cytochrome c has been shown repeatedly to induce
processing and activation of caspase-3, which in turn cleaves
the endogenous substrate PARP. Therefore, we investigated
whether TUDCA could prevent the release of mitochondrial
factors that induce DEVD-specific caspase activation. Mi-
tochondrial supernatants from the various test groups were
incubated with cytosolic fractions from primary rat hepato-
cytes, and caspase-3 like activity measured using DEVD-
pNA as a substrate. Supernatants from Bax-treated mito-
chondria resulted in a marked elevation in DEVD-cleaving
activity that increased with prolonged exposure (Figure 3A).
In contrast, pretreatment of mitochondria with TUDCA
consistently prevented caspase activation, and reduced
FIGURE 2: TUDCA inhibits Bax-induced release of cytochromec
in isolated mitochondria. Mitochondria were isolated from rat liver
and incubated with either no addition (control), 0.5µM Bax, 500
µM TUDCA, 5 µM cyclosporine A (CsA), Bax+ TUDCA, or
Bax + CsA for 5 min. In coincubation experiments, mitochondria
were pretreated with TUDCA or CsA for 5 min. Mitochondrial
pellets and supernatants were examined for cytochromec levels
by Western blot analysis (top). Following SDS-polyacrylamide
gel electrophoresis and transfer, the nitrocellulose membranes were
incubated with the monoclonal antibody to cytochromec and the
15-kDa protein was detected using ECL chemiluminescence. The
accompanying histograms are the densitometric means( SEM
relative to control (pellet) or Bax (supernatant) for at least three
independent experiments (bottom).†p < 0.05 and *p < 0.01 from
control, and§p < 0.01 from Bax.
Table 1: Time-Dependent Inhibition of Cytochromec Release and
Caspase Activity by TUDCAa
inhibition (%)
incubation time (min) cytochromec release caspase activity
1 56.1( 6.9 40.3( 4.9
5 60.5( 5.2 43.1( 3.5
20 63.3( 6.5 49.4( 2.9
60 74.2( 11.1 59.3( 5.2
a Mitochondria were isolated from rat liver and incubated with either
no addition (control), 0.5µM Bax, 500µM TUDCA, or Bax+ TUDCA
for 1, 5, 20, and 60 min. Mitochondrial supernatants were examined
for cytochromec levels by Western blot analysis. In addition, cytosolic
protein extracts were prepared from primary rat hepatocytes and
incubated with supernatants from Bax-treated mitochondria. Caspase
activity was measured using the colorimetric substrate DEVD-pNA in
cytososlic fractions after incubation with supernatants from the treated
mitochondria. In coincubation experiments, mitochondria were pre-
treated with TUDCA for 5 min. Data were calculated as means( SEM
relative to controls for at least three separate experiments.
FIGURE 3: TUDCA inhibits Bax-induced activation of DEVD-
specific caspases. Cytosolic protein extracts were prepared from
primary rat hepatocytes and incubated with supernatants from Bax-
treated mitochondria. Caspase activity was measured using the
colorimetric substrate DEVD-pNA as described in Materials and
Methods. (A) DEVD-specific caspase activity in cytososlic fractions
after incubation with supernatants from mitochondria treated with
0.5µM Bax for either 0 (control), 1, 5, 20, and 60 min. (B) TUDCA
inhibition of DEVD-specific caspase activation in cytosolic fractions
after incubation with supernatants from mitochondria treated with
either no addition (control), 0.5µM Bax, 500µM TUDCA, or Bax
+ TUDCA for 5 min. In coincubation experiments, mitochondria
were pretreated with TUDCA for 5 min. Data are means( SEM
values for at least three different experiments. *p < 0.01 from
control; §p < 0.01 from Bax.
3074 Biochemistry, Vol. 42, No. 10, 2003 Rodrigues et al.
enzyme activity to significantly lower levels (p < 0.01).
Incubation with Bax plus TUDCA for 1, 5, 20, and 60 min
reduced caspase activation∼40, 45, 50, and 60%, respec-
tively, compared to Bax alone (Table 1). Thus, it required
about 20 min of incubation with TUDCA to reduce caspase
activity to half of the maximum activation induced by Bax
alone. This suggests that apoptotic factors in addition to
cytochromec may be involved in caspase activation. Neither
Bax nor isolated mitochondria alone were activators of
DEVD-cleaving caspases (data not shown). Western blot
analysis of the same cytosolic extracts revealed that super-
natants derived from Bax-treated mitochondria induced a
concentration- and time-dependent proteolytic processing of
caspase-3 (Figure 4A). The active caspase-3 fragment was
increased 1.6-fold after 1 min incubation with Bax, almost
3-fold at 20 min, and remained the same at 60 min. In
contrast, TUDCA co-incubation resulted in more than a 40%
reduction in active caspase-3 after 5 min of incubation
(Figure 4B).
Although our results indicated that TUDCA prevented
Bax-induced release of cytochromec and the subsequent
activation and processing of cytosolic caspases, it did not
significantly modulate expression of Bax by RT-PCR in
isolated hepatocytes (data not shown). Thus, it appears that
TUDCA markedly alters the interaction of Bax with mito-
chondrial membranes without modulating gene expression.
It remains to be determined whether transcript and/or protein
stability are altered by the hydrophilic bile acid.
TUDCA PreVents Bax Binding and Insertion into Mito-
chondrial Membranes.Levels of endogenous Bax protein
in control rat liver mitochondria were almost undetectable
by Western blot analysis (Figure 5A). Incubation with Bax,
however, resulted in a rapid increase in the levels of the
proapoptogenic protein either inserted and/or associated with
the isolated mitochondria. Co-incubation with TUDCA
reduced these levels by∼70% (p < 0.01), which was similar
to the observed decrease in cytochromec r lease. In contrast,
cyclosporine A did not significantly reduce the levels of Bax
protein associated with the mitochondria. When the mito-
chondria were extracted with carbonate, however, essentially
all of the remaining Bax protein from incubations with either
Bax alone, TUDCA or CsA was recovered in the supernatant
(Figure 5B). The results indicated that TUDCA but not
cyclosporine A significantly reduced Bax association with
the mitochondrial membrane. In addition, neither TUDCA
nor cyclosporine A increased Bax levels that were nonex-
tractable from the mitochondrial membrane (p < 0.01),
consistent with the results from Table 2.
TUDCA PreVents Bax-Induced Alterations in Mitochon-
drial Membrane Lipid Polarity, Protein Order, and Redox
Status.EPR studies were designed to test whether Bax could
induce macromolecular membrane structural perturbation and
cytochromec release in isolated mitochondria in the absence
of permeability transition pore opening. We investigated the
effect of Bax on mitochondrial membrane polarity at varying
depths using 5- and 16-DSA spin labels and determined
several spectroscopic parameters (Figure 6). Bax interaction
with mitochondria resulted in an almost 10% increase in
membrane polarity at both the 5-DSA superficial and 16-
DSA deeper layers of the membrane leaflet (p < 0.05) (Table
2). In addition, the motion parameters∆l andh+1/h0 reflected
a 20% increase in membrane fluidity at C-5 (p < 0.01), but
only a 5% change at C-16 (p < 0.05). These results suggest
that Bax interacts preferably with superficial regions of the
membrane, resulting in loose association with mitochondria.
In contrast, TUDCA alone marginally altered dynamic
properties of the mitochondrial membranes. However, pre-
treatment with TUDCA partially prevented the Bax-induced
FIGURE 4: TUDCA inhibits Bax-induced proteolytic processing of
caspase-3. Cytosolic protein extracts were prepared from primary
rat hepatocytes and incubated with supernatants from Bax-treated
mitochondria. Caspase-3 processing was examined by Western blot.
Following SDS-polyacrylamide gel electrophoresis and transfer,
the nitrocellulose membranes were incubated with the polyclonal
antibody to caspase-3 and the active 20-kDa protein was detected
by ECL chemiluminescence. (A) Caspase-3 processing in cytosolic
fractions after incubation with supernatants from mitochondria
treated with no addition (control), 0.5, 1, or 2µM Bax for 5 min
(left). In addition, mitochondria were incubated with 0.5µM Bax
for 0 (control), 1, 5, 20, or 60 min (right). (B) TUDCA inhibition
of caspase-3 processing after incubation with supernatants from
mitochondria treated with either no addition (control), 0.5µM Bax,
500 µM TUDCA, or Bax + TUDCA for 5 min. In coincubation
experiments, mitochondria were pretreated with TUDCA for 5 min.
FIGURE 5: TUDCA inhibits binding of Bax to isolated mitochon-
dria. Mitochondria were isolated from rat liver and incubated with
no addition (control), 0.5µM Bax, 500 µM TUDCA, 5 µM
cyclosporine A (CsA), Bax+ TUDCA, or Bax+ CsA for 5 min.
In coincubation experiments, mitochondria were pretreated with
TUDCA or CsA for 5 min. (A) Mitochondrial levels of Bax protein
were determined by Western blot analysis (top). Following SDS-
polyacrylamide gel electrophoresis and transfer, the nitrocellulose
membranes were incubated with the polyclonal antibody to Bax
and the 21-kDa protein was detected using ECL chemiluminescence.
The accompanying histogram is the densitometric means( SEM
relative to Bax for at least three independent experiments (bottom).
*p < 0.01 from control;§p < 0.01 from Bax. (B) Carbonate
extraction was performed on mitocondrial Bax and the supernatant
and pellet fractions were visualized by Western blot analysis for
extractable and nonextractable Bax protein, respectively.
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increase in lipid polarity (p < 0.05), while almost completely
inhibiting changes in mitochondrial membrane lipid fluidity
(p < 0.01) both at C-5 and C-16. Cyclosporine A, although
protective of deeper membrane changes, did not significantly
prevent the superficial interaction of Bax. These results
support the carbonate extraction data in that TUDCA, but
not cyclosporine A, inhibits superficial binding of Bax to
mitochondria.
Using the protein-oriented spin label 4-maleimido-
TEMPO, the mobility parameterh0/h-1 was significantly
increased after exposure to Bax (p < 0.01). The results
reflected decreased mobility of the probe and greater
structural order in mitochondrial membrane proteins at the
surface level, consistent with loose association of Bax with
the membrane (Table 2). In contrast, pretreatment with
TUDCA completely abrogated Bax-induced effects, and
decreased protein order to control levels (p < 0.01). Washout
experiments were performed in which TUDCA was removed
from the incubation medium prior to incubation with Bax.
The results were similar and suggested that the inhibitory
effect of TUDCA did not occur from a direct interaction
between the bile acid and Bax protein in the incubation
media. Furthermore, the spectra obtained from mitochondria
incubated only with TUDCA revealed no differences between
the washout and standard incubation conditions (data not
shown).
We then determined if exposure to Bax directly modified
levels of mitochondrial membrane lipid oxidation. Isolated
mitochondria were probed with 5-DSA spin label and then
exposed to Bax (Figure 7). Bax caused a rapid loss of spin-
probe intensity, manifested by a>30% decrease in peak
amplitude (p < 0.01). Using a different methodological
approach to measure signal intensity, based on the double
integration of spectra, we confirmed the results described
above (data not shown). Spin-label signal amplitude in
isolated mitochondria was also assessed in the presence of
TUDCA. Treatment of 5-DSA-labeled mitochondria with the
bile acid alone did not significantly decrease signal ampli-
tude, while incubation with TUDCA for 5 min prior to
exposure to Bax markedly inhibited oxidative lipid injury
(p < 0.01). This protection resulted in signal amplitudes that
were no different from controls. The results suggested that
TUDCA either directly confers protection against lipid
peroxidation in isolated mitochondrial membranes, or indi-
rectly prevents reactive oxygen species production by
interfering with Bax interaction with the membrane. Cy-
closporine A was less effective at preventing Bax-induced
spectral changes.
Table 2: TUDCA Prevents Bax-Induced Alterations in Mitochondrial Membrane Lipid Polarity and Fluidity, and Protein Ordera
5-DSA 16-DSA 4-maleimido-TEMPO
lipid polarity a0 lipid fluidity ∆l lipid polarity a0 lipid fluidity h+1/h0 protein orderh0/h-1
control 1.00( 0.02 1.00( 0.10 1.00( 0.03 1.00( 0.02 1.00( 0.01
Bax 1.09( 0.03* 1.25( 0.07* 1.10( 0.04† 1.06( 0.02† 1.12( 0.02*
TUDCA 1.02( 0.01 1.09( 0.12 1.03( 0.03 0.97( 0.01 0.93( 0.05
Bax + TUDCA 1.04( 0.01‡ 1.03( 0.12§ 1.04( 0.01‡ 0.93( 0.01§ 0.96( 0.02§
CsA 1.05( 0.02 1.03( 0.01 1.03( 0.02 1.02( 0.01 1.00( 0.01
Bax + CsA 0.99( 0.02‡ 1.19( 0.16 1.04( 0.03 0.92( 0.03§ 1.03( 0.02‡
a Mitochondria were labeled with the 5-DSA, 16-DSA, and 4-maleimido-TEMPO spin probes and incubated with either no addition (control),
0.5 µM Bax, 500µM TUDCA, 5 µM cyclosporine A (CsA), Bax+ TUDCA, or Bax+ CsA for 5 min. In coincubation experiments, mitochondria
were pretreated with TUDCA or CsA for 5 min. Mitochondrial pellets were examined for lipid polarity and fluidity, as well as protein order by
EPR spectroscopy analyses. The 5- and 16-DSA spin labels were used to sense alterations in mitochondrial membrane isotropic hyperfine splitting
constant (a0). Changes in the half-width at half-height (/2) of the low-field extremum or∆l and in the ratio of the height of the low-field line (h+1)
to the height of the midline (h0) were calculated for the 5-DSA and the 16-DSA spin labels, respectively. Alterations in the ratio of the height of
the midline (h0) to the height of the high-field line (h-1) were measured by the 4-maleimido-TEMPO spin label. Values are means( SEM for at
least three separate experiments.†p < 0.05 and *p < 0.01 from control;‡p < 0.05 and§p < 0.01 from Bax.
FIGURE 6: Spectral parameters of spin labels incorporated into
mitochondrial membranes. (A) Spectra of nitroxide-labeled stearic
acids and measurements of maximum (A|) and minimum (A⊥)
hyperfine splittings to estimatea0 [a0 ) 1/3(A| + 2A⊥)] for 5- and
16-DSA spin labels (a); outer half-with at half-height (/2) of the
low-field extremum or∆l calculated for the 5-DSA spin label (b);
ratio of the height of the low-field line (h+1) to the height of the
midline (h0) calculated for the 16-DSA spin label (c). (B) spectrum
of 4-maleimido-TEMPO label and measurement of the ratio of the
height of the midline (h0) to the height of the high-field line (h-1).
All spectra were acquired at 9.8 GHz (X-band) on a Bruker EMX
EPR spectrometer using a rectangular ER 4102ST cavity and 100
kHz field modulation frequency, 1.05 G modulation amplitude, and
20 mW microwave power, at 22°C.
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DISCUSSION
In the present study, we have demonstrated that (a) the
addition of recombinant Bax protein to isolated mitochondria
can induce cytochromec release; (b) Bax-mediated release
of cytochromec occurs in the apparent absence of perme-
ability transition and subsequent swelling that is thought to
rupture the outer mitochondrial membrane; (c) altered
membrane lipid polarity and fluidity, protein order, and redox
status accompany the insertion of Bax into the mitochondrial
membrane; and (d) mitochondria treated with TUDCA prior
to addition of Bax are resistant to Bax-induced alterations.
These observations support the notion that TUDCA alters
the ability of Bax to interact with the mitochondrial
membrane, thereby preventing the induced perturbation.
Thus, at least one mechanism for the antiapoptotic effect of
TUDCA is related to its ability to modulate Bax association
with mitochondria, and it appears to do so without directly
interacting with the protein in solution.
UDCA and its conjugated derivatives play a unique role
in modulating the apoptotic threshold in both hepatic and
nonhepatic cells (27-29). The inhibition of cytochromec
release and downstream caspase activation in apoptotic cells
by these bile acids suggested that the hydrophilic bile acid
might act at the mitochondrial level. The interaction of
UDCA with the mitochondrial membrane was recently
demonstrated in a study where the fluorescent-labeled UDCA
colocalized with mitochondria in cultured hepatocytes (50).
Thus, the protective effects of UDCA and TUDCA in intact
cells at micromolar concentrations are thought to result, in
part, from modulation of Bax translocation from cytosol to
mitochondria, together with inhibition of mitochondrial
depolarization and outer membrane rupture (51).
To establish a direct effect of TUDCA on mitochondria,
we first examined whether recombinant Bax alone was
sufficient to trigger membrane perturbation. We then inves-
tigated the ability of TUDCA to prevent those changes.
Previous studies have demonstrated the importance of the
BH3 domain of Bax for homo- and heterodimerization with
other antiapoptotic Bcl-2 family proteins (52). In contrast
to monomeric recombinant Bax, oligomeric Bax forms
channels large enough to allow the release of cytochromec
from liposomes (53, 54). It is therefore conceivable that Bax
directly constitutes the structural entirety of a channel in the
outer mitochondrial membrane that permits cytochromec
release (55). In this model, Bax and Bak are activated by
BH3-only factors forming tetrameric channels that allow the
release of apoptogenic factors from the mitochondrial inter-
membrane space. Genetic knockout analysis suggests that
Bax and Bak are indeed essential to mitochondrial dysfunc-
tion and subsequent cell death by a wide variety of stimuli
(56). However, it remains controversial as to whether
truncated Bid is required to induce Bax oligomerization and
cluster formation in the outer mitochondrial membrane. In
fact, it was recently reported that Bax can induce cytochrome
c release and loss of membrane potential in the absence of
Bid or Bak translocation to the mitochondria (57).
These in situ experiments suggest that Bid may only be
required in certain, but not all cell types. Alternatively, Bax
might indirectly alter membrane permeability through inter-
action with other proteins. To this end, Bax, but not Bcl-2
or Bcl-x, was found to copurify with the permeability
transition pore (58). In addition, it has been suggested that
Bax and Bak, but not BH3-only factors, can cause∆Ψm
collapse in isolated mitochondria (59). According to this
model, Bax binds to the permeability transition pore complex,
resulting in its opening, swelling of the mitochondrial matrix
and rupture of the outer mitochondrial membrane (60).
Interaction between the voltage-dependent anion channel and
the mitochondrial permeability transition pore remains
unclear. In fact, cytochromec release can occur in the
absence of mitochondrial swelling and megapore activation
(16). Further, cross-linking studies failed to demonstrate an
interaction between Bax and the voltage-dependent anion
channel (61), while Bax has been shown to directly release
cytochromec from isolated mitochondria (15). It was also
shown that increased membrane permeability may be at-
tributed to a new channel, the mitochondria-apoptosis-
induced channel, located in the outer mitochondrial mem-
brane (62). This channel, although similar to the Bax/Bak
channel, may contain additional components that allow the
release of larger-sized factors, such as Smac/DIABLO, and
simultaneously provide a type of gating system. Interestingly,
it was recently demonstrated that mitochondrial lipid rather
than protein composition is the key determinant in the
permeabilization process induced by Bax via a supramo-
lecular complex (24).
In this study, we confirm that the addition of purified Bax
to isolated mitochondria is sufficient to directly induce release
of cytochromec (15, 16) in the absence of permeability
changes that cause mitochondrial swelling. This suggests that
Bax plays a key role in mediating cytochromec release
during apoptosis, perhaps by acting independently of the
permeability transition pore opening. Our results, however,
differ from those reported in an earlier study in which
recombinant Bax caused a sustained opening of the mito-
chondrial permeability transition pore with subsequent
persistent organelle swelling and deenergization (63). Nev-
ertheless, their experimental design used truncated recom-
binant Bax instead of the full-length protein and their
purification procedure involved exposures to low pHs and
FIGURE 7: TUDCA prevents Bax-induced oxidative injury in
isolated mitochondrial membranes. Mitochondria were labeled with
the 5-DSA spin probe and incubated with no addition (control),
0.5 µM Bax, 500µM TUDCA, 5 µM cyclosporine A (CsA), Bax
+ TUDCA, or Bax+ CsA for 5 min. In coincubation experiments,
mitochondria were pretreated with TUDCA or CsA for 5 min.
Mitochondrial pellets were examined for lipid oxidative damage
by EPR spectroscopy analyses. Individual values of signal amplitude
and means( SEM relative to controls are representative of at least
three separate experiments. All spectra were acquired at 9.8 GHz
(X-band) on a Bruker EMX EPR spectrometer using a rectangular
ER 4102ST cavity and 100 kHz field modulation frequency, 1.05
G modulation amplitude, and 20 mW microwave power, at 22°C.
TUDCA Inhibits Bax Interaction with Mitochondria Biochemistry, Vol. 42, No. 10, 20033077
detergents which induce significant conformational changes
in the protein. Further, the finding that cyclosporine A failed
to block Bax-induced cytochromec release supports the
notion that the release of intermembrane proteins does not
necessarily involve disruption of the megapore. Although
we have not excluded the possibility that Bax interacts with
other components of the permeability transition pore, these
results suggest that the pro-apoptotic protein triggers cyto-
chromec release independently of at least cyclophilin D.
Different methodological conditions, such as the presence
or absence of calcium chelators in the incubation medium,
may account for contradictory results published by different
groups (15, 16). In fact, a protective effect by cyclosporine
A may reflect the inhibition of calcium-activated permeability
transition rather than Bax-induced changes.
In addition to cytochromec release and subsequent caspase
processing and activation, EPR analysis indicated that Bax
also induced marked changes in lipid and protein structure
of the mitochondrial membranes. The ability of Bax to
increase fluidity and permeability of membrane lipids at
superficial membrane regions is consistent with its loose
association with mitochondria. Moreover, increased surface
protein order in mitochondrial membranes exposed to Bax
is compatible with its binding to the membrane, thus reducing
the mobility of other structural proteins. Therefore, Bax may
become active only after interaction with the mitochondrial
membrane. This is consistent with recent results demonstrat-
ing that oligomeric Bax forms complexes with mitochondrial
membrane proteins in cultured cells exposed to staurosporine
or UV radiation (55). Interestingly, the direct interaction of
Bax with mitochondrial membrane may occur only briefly
during apoptosis, coalescing thereafter with other proapop-
totic proteins into clusters adjacent to mitochondria (64).
When mitochondria were treated with TUDCA, we were
unable to detect any major changes in membrane dynamic
properties. This was not surprising considering the hydro-
philic qualities of the bile acid. However, our results indicate
that TUDCA was able to alter the membrane environment
and inhibit Bax protein from interacting to form channels
and disrupting lipid dynamics. This is consistent with
supramolecular openings in the outer mitochondrial mem-
brane induced by the interaction of Bax with membrane lipids
(24) and inhibited by TUDCA. It remains to be determined
how TUDCA associates with the membrane for a prolonged
inhibitory effect on Bax. It is also unclear whether specific
lipids in mitochondrial membranes, such as cardiolipin,
would affect the ability of TUDCA to abrogate Bax-induced
changes in membrane lipid fluidity and polarity. Interestingly,
the mitochondrial cardiolipin content was shown to be
significantly greater in bile duct-ligated rats, with increased
levels of hydrophobic bile acids (65). Finally, the washout
experiments suggest that the effect of TUDCA does not occur
by interaction of the bile acid with Bax in solution. Rather,
the protective effect appears to be mediated at the outer
membrane, resulting in significantly reduced levels of
cytochromec in the supernatants of mitochondria incubated
with both Bax and TUDCA. Not surprisingly, TUDCA also
prevented the generation of reactive oxygen species from
failed electron chain transport after cytochromec realease.
Under these conditions, most cytochromec remained as-
sociated with the inner membrane to sustain electron transport
chain. The small proportion of cytochromec released from
mitochondria incubated with Bax plus TUDCA only mod-
estly triggered caspase activation as compared to mitochon-
dria exposed to Bax alone.
Interestingly, the partial inhibition of Bax-induced struc-
tural changes in membrane motion by cyclosporine A
suggests that the effect on Bax function is indirect, and occurs
primarily at deeper membrane regions. In such scenario,
cyclosporine A appears to inhibit secondary opening of the
megapore altering the overall environment of lipids and
proteins, which collaborate with Bax to induce membrane
permeability and fluidity. This, however, does not prevent
loose association of Bax protein with the outer membrane,
nor does it influence cytochromec release through the Bax
channel, which is very rapid and complete. The results
suggest that both TUDCA and cyclosporine A act at the
mitochondrial membrane. However, TUDCA stabilizes the
lipid and protein structure, thus inhibiting Bax binding. This
is in contrast to cyclosporine A that allows association but
prevents deeper structural changes and opening of the
megapore secondary to uncoupled oxidative phosphorylation.
In conclusion, we have demonstrated that Bax can directly
trigger the release of cytochromec in isolated mitochondria,
and appears to do so independently of the mitochondrial
permeability transition pore. Although not severely affected,
the physical properties of membrane lipids and proteins
reflect association of Bax with the mitochondrial membrane
and the subsequent release of cytochromec. In clear contrast,
pretreatment with TUDCA partially inhibited Bax binding
and subsequent events, including the release of mitochondrial
factors that trigger cytosolic caspase activation. Our results
suggest that the antiapoptotic properties of TUDCA occur,
in part, by inhibition of Bax through direct stabilization of
the mitochondrial membrane by the bile acid.
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